The role of systemic corticosteroids in severe asthma and new evidence in their management and tapering

References

• Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276–293.
   PubMed Web of Science ®Google Scholar
• Heffler E, Blasi F, Latorre M, et al. The severe asthma network in Italy: findings and perspectives. J Allergy Clin Immunol Pract. 2019;7:1462–1468.
   PubMed Web of Science ®Google Scholar
• Backman H, Jansson SA, Stridsman C, et al. Severe asthma-A population study perspective. Clin Exp Allergy. 2019;49:819–828.
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Charmandari E, Kino T, et al. Stress-related and circadian secretion and target tissue actions of glucocorticoids: impact on health. Front Endocrinol (Lausanne). 2017;8:70.
   PubMed Web of Science ®Google Scholar
• Zazzali JL, Broder MS, Omachi TA, et al. Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. Allergy Asthma Proc. 2015;36(4):268–274.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136:1488–1495.
   PubMed Web of Science ®Google Scholar
• Manson SC, Brown RE, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975–994.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012;185:1286–1291.
   PubMed Web of Science ®Google Scholar
• Phipatanakul W, Mauger DT, Sorkness RL, et al. Effects of age and disease severity on systemic corticosteroid responses in asthma. Am J Respir Crit Care Med. 2017;195:1439–1448.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. How do corticosteroids work in Asthma? Ann Intern Med. 2003;139:359–370.
   PubMed Web of Science ®Google Scholar
• Ye Q, He XO, D’Urzo A. A review on the safety and efficacy of inhaled corticosteroids in the management of asthma. Pulm Ther. 2017;3:1–18.
   Google Scholar
• Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203–207.
   PubMedGoogle Scholar
• Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–670.
   PubMed Web of Science ®Google Scholar
• Koper JW, van Rossum EF, van Den Akker EL. Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids. 2014;92:62–73.
   PubMed Web of Science ®Google Scholar
• Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab. 2008;19:331–339.
   PubMed Web of Science ®Google Scholar
• Panek M, Pietras T, Fabijan A, et al. Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes. Exp Ther Med. 2013;5(2):572–580.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Ford PA, Bhavsar P, et al. Steroid resistance in asthma: mechanisms and treatment options. Curr Allergy Asthma Rep. 2008;8:171–178.
   PubMed Web of Science ®Google Scholar
• Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2006;117(3):522–543.
   PubMed Web of Science ®Google Scholar
• Irusen E, Matthews JG, Takahashi A, et al. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol. 2002;109:649–657.
   PubMed Web of Science ®Google Scholar
• Adcock I, Lane S. Mechanisms of steroid action and resistance in inflammation. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol. 2003;178(3):347–355.
   PubMed Web of Science ®Google Scholar
• Loke TK, Mallett KH, Ratoff J, et al. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol. 2006;118(2):368–375.
   PubMed Web of Science ®Google Scholar
• Gunawardhana L, Gibson PG, Simpson JL, et al. Activity and expression of histone acetylases and deacetylases in inflammatory phenotypes of asthma. Clin Exp Allergy. 2014;44:47–57.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Histone deacetylase-2 and airway disease. Ther Adv Respir Dis. 2009;3(5):235–243.
   PubMedGoogle Scholar
• Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kδ restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med. 2009;179:542–548.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Ito K, Barnes PJ. Histone deacetylation: an important mechanism in inflammatory lung diseases. COPD. 2005;2:445–455.
   PubMedGoogle Scholar
• Yin H, Liu MH, Gao F, et al. Pro-inflammatory and pro-fibrotic role of long non-coding RNA RMRP in pediatric asthma through targeting microRNA-206/CCL2 axis. J Biol Regul Homeost Agents. 2021;35(1):71–83.
   PubMed Web of Science ®Google Scholar
• Pietruczuk M, Kraszula L, Kupczyk M, et al. Dynamics and proliferative capacities of CD8+CD28+TCRαβ+CD62Lhigh T-cell subsets in healthy and asthmatic subjects. J Biol Regul Homeost Agents. 2021;35(2):485–494.
   PubMed Web of Science ®Google Scholar
• Kauppi P, Peura S, Salimaki J, et al. Reduced severity and improved control of self-reported asthma in Finland during 2001-2010. Asia Pac Allergy. 2015;5(1):32–39.
   PubMed Web of Science ®Google Scholar
• Von Bulow A, Kriegbaum M, Backer V, et al. The prevalence of severe asthma and low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2:759–767.
   PubMed Web of Science ®Google Scholar
• Eger K, Amelink M, Hashimoto S, et al. Overuse of oral corticosteroids, underuse of inhaled corticosteroids, and implications for biologic therapy in Asthma. Respiration. 2021;1–6: https://doi.org/10.1159/000518514
   Google Scholar
• Hew M, McDonald VM, Bardin PG, et al. Cumulative dispensing of high oral corticosteroid doses for treating asthma in Australia. Med J Aust. 2020;213:316–320.
   PubMed Web of Science ®Google Scholar
• Ameli F, Mignosi S, Brocchetti F, et al. Sleep-disordered breathing in the otorhinolaryngological practice. J Biol Regul Homeost Agents. 2021 Jan-Feb;35:27–32.
   PubMedGoogle Scholar
• Zeiger R, Sullivan P, Chung Y, et al. Systemic corticosteroid-related complications and costs in adults with persistent asthma. J Allergy Clin Immunol Pract. 2020;8(10):3455–3465.e13.
   PubMed Web of Science ®Google Scholar
• Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.
   PubMed Web of Science ®Google Scholar
• Benard-Laribiere A, Pariente A, Pambrun E, et al. Prevalence and prescription patterns of oral glucocorticoids in adults: a retrospective cross-sectional and cohort analysis in France. BMJ Open. 2017;7:e015905.
   PubMed Web of Science ®Google Scholar
• Choo XN, Pavord ID. Morbidity associated with oral corticosteroids in patients with severe asthma. Thorax. 2016;71:302–304.
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids in the United Kingdom. QJM. 2000;93(2):105–111.
   PubMed Web of Science ®Google Scholar
• Farber HJ, Silveira EA, Vicere DR, et al. Oral corticosteroid prescribing for children with asthma in a Medicaid managed care program. Pediatrics. 2017;139(5):e20164146.
   PubMed Web of Science ®Google Scholar
• Arabkhazaeli A, Vijverberg SJ, van der Ent CK, et al. High incidence of oral corticosteroids prescriptions in children with asthma in early childhood. J Asthma. 2016;53(10):1012–1017.
   PubMed Web of Science ®Google Scholar
• Tran TN, MacLachlan S, Hicks W, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allergy Clin Immunol Pract. 2021;9:338–346.e3.
   PubMed Web of Science ®Google Scholar
• Wark PA, McDonald VM, Gibson PG. Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma. Respirology. 2015;20(8):1282–1284.
   PubMed Web of Science ®Google Scholar
• Hanratty CE, Matthews JG, Arron JR, et al. A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial. Trials. 2018;19:5.
   PubMed Web of Science ®Google Scholar
• Pinnock H. Supported self-management for asthma. Breathe. 2015;11:98–99.
   Web of Science ®Google Scholar
• Maijers I, Kearns N, Harper J, et al. Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma. Eur Respir J. 2020;55:1901147.
   PubMed Web of Science ®Google Scholar
• Masoli M, Weatherall M, Holt S, et al. Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis. Eur Respir J. 2006;28(5):960–967.
   PubMed Web of Science ®Google Scholar
• Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalmic-pituitary-adrenal axis in asthmatic subjects: a dose-response study. J Allergy Clin Immunol. 1998;101(3):312–319.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Suehs C, Charriot J. Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship. Eur Respir J. 2020;55(1):1902193.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2021. [ Retrieved 2021 Jul 18] https://ginasthma.org/gina-reports/
   Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55:1900588.
   PubMed Web of Science ®Google Scholar
• National Asthma Council Australia. Australian Asthma Handbook, version 1.3. Melbourne: National Asthma Council Australia; 2017. [Accessed 2021 Jul 18]. https://www.asthmahandbook.org.au/.
   Google Scholar
• FitzGerald JM, Lemiere C, Lougheed MD, et al. Recognition and management of severe asthma: a Canadian Thoracic Society position statement. Can J Respir Crit Care Sleep Med. 2017;1(4):199–221.
   Web of Science ®Google Scholar
• Ramsahai JM, Wark PA. Appropriate use of oral corticosteroids for severe asthma. Med J Aust. 2018;209(S2):S18–S21.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Blasi F, Paggiaro P, et al. Oral CorticoSteroid sparing with biologics in severe asthma: a remark of the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2020;13:100464.
   PubMed Web of Science ®Google Scholar
• McDonald VM, Hiles SA, Godbout K, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24:37–47.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Brightling CE, Menzies-Gow A, et al. Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry. Thorax. 2010;65(9):787–794.
   PubMed Web of Science ®Google Scholar
• Clark VL, Gibson PG, Genn G, et al. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology. 2017;22:1262–1275.
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, et al. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39:2216–2229.
   PubMed Web of Science ®Google Scholar
• Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71:339–346.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. New Engl J Med. 2017;376(25):2448–2458.
   PubMed Web of Science ®Google Scholar
• Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104:1381–1385.
   PubMed Web of Science ®Google Scholar
• https://www.medicines.org.uk/emc/product/7238/smpc#gref. [ Retrieved 2021 Jul 30]
   Google Scholar
• Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of short-course oral corticosteroids in children. Arch Dis Child. 2016;101:365–370.
   PubMed Web of Science ®Google Scholar
• McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid associated adverse events. Curr Opin Rheumatol. 2008;20(2):131–137.
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415.
   PubMed Web of Science ®Google Scholar
• Yao TC, Huang YW, Chang SM, et al. Association between oral corticosteroid bursts and severe adverse events: a nationwide population-based cohort study. Ann Intern Med. 2020;173(5):325–330.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH, Globe G, et al. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141:110–116.e7.
   PubMed Web of Science ®Google Scholar
• Ekstrom M, Nwaru BI, Hasvold P, et al. Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden. Allergy. 2019;74:2181.
   PubMed Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–194.
   PubMed Web of Science ®Google Scholar
• Matsunaga K, Adachi M, Nagase H, et al. Association of low-dosage systemic corticosteroid use with disease burden in asthma. NPJ Prim Care Respir Med. 2020;30:35.
   PubMed Web of Science ®Google Scholar
• Bloechliger M, Reinau D, Spoendlin J, et al. Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis. Respir Res. 2018;19:75.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Duh MS, and Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016;22(7):833-847.
   Google Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–963.
   PubMedGoogle Scholar
• Fardet L, Petersen I, Nazareth I. Common infections in patients prescribed systemic glucocorticoids in primary care: a population-based cohort study. PLoS Med. 2016;13:e1002024.
   PubMed Web of Science ®Google Scholar
• Palmsten K, Bandoli G, Watkins J, et al. Oral corticosteroids and risk of preterm birth in the California medicaid program. J Allergy Clin Immunol Pract. 2021;9:375–384.e5.
   PubMed Web of Science ®Google Scholar
• Lee H, Ryu J, Nam E, et al. Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Eur Respir J. 2019;54:1900804.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Molinari N, Vachier I, et al. Mortality: a neglected outcome in OCS-treated severe asthma. Eur Respir J. 2017;50(5):1701486.
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Duh MS, Lafeuille MH, et al. Burden of systemic glucocorticoid-related complications in severe asthma. Curr Med Res Opin. 2017;33:57–65.
   PubMed Web of Science ®Google Scholar
• Daugherty J, Lin X, and Baxter R, et al. The impact of long-term systemic glucocorticoid use in severe asthma: a UK retrospective cohort analysis. J Asthma. 2018;55(6):651–658.
   Web of Science ®Google Scholar
• Zeiger RS, Schatz M, Li Q, et al. Burden of chronic oral corticosteroid use by adults with persistent asthma. J Allergy Clin Immunol Pract. 2017;5:1050–1060.
   PubMed Web of Science ®Google Scholar
• Barry LE, Sweeney J, O’Neill C, et al. The cost of systemic corticosteroid induced morbidity in severe asthma: a health economic analysis. Respir Res. 2017;18:129.
   PubMed Web of Science ®Google Scholar
• Janson C, Lisspers K, Ställberg B, et al. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR). Respir Res. 2018;19:168.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organ J. 2019;12:100007.
   PubMed Web of Science ®Google Scholar
• Tarantini F, Baiardini I, Passalacqua G, et al. Asthma treatment: ‘magic bullets which seek their own targets. Allergy. 2007;62(6):605–610.
   PubMed Web of Science ®Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–166.
   PubMedGoogle Scholar
• Menzella F, Ruggiero P, Ghidoni G, et al. Anti-IL5 therapies for severe eosinophilic asthma: literature review and practical insights. J Asthma Allergy. 2020;13:301–313.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al.; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting b(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al.; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2141.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496.
   PubMed Web of Science ®Google Scholar
• Katsaounou P, Buhl R, Brusselle G, et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir Med. 2019;150:51–62.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Prazma CM, Chupp GL. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021;22:171.
   PubMed Web of Science ®Google Scholar
• Menzella F, Biava M, Bagnasco D, et al. Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? Drugs Context. 2019;8:212580.
   PubMedGoogle Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475–2485.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Aiello M, Frizzelli A, et al. Oral corticosteroids dependence and biologic drugs in severe asthma: myths or facts? A systematic review of real-world evidence. Int J Mol Sci. 2021;22:7132.
   PubMed Web of Science ®Google Scholar
• Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med. 2009;180:388–395.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Fouka E, Papakosta D, et al. Switching between biologics in severe asthma patients. When the first choice is not proven to be the best. Clin Exp Allergy. 2021;51:221–227.
   PubMed Web of Science ®Google Scholar
• Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180:817–822.
   PubMed Web of Science ®Google Scholar
• Lindsay JT, Heaney LG. Nonadherence in difficult asthma - facts, myths, and a time to act. Patient Prefer Adherence. 2013;7:329–336.
   PubMed Web of Science ®Google Scholar
• Caminati M, Vianello A, Andretta M, et al. Low adherence to inhaled corticosteroids/long-acting β2-agonists and biologic treatment in severe asthmatics. ERJ Open Res. 2020;6(2):00017.
   PubMedGoogle Scholar
• Porsbjerg C, Ulrik C, Skjold T, et al. Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. Eur Clin Respir J. 2018;5:1440868.
   PubMed Web of Science ®Google Scholar
• Kayani S, Shannon DC. Adverse behavioral effects of treatment for acute exacerbation of asthma in children: a comparison of two doses of oral steroids. Chest. 2002;122(2):624–628.
   PubMed Web of Science ®Google Scholar
• Burke H, Davis J, Evans S, et al. A multidisciplinary team case management approach reduces the burden of frequent asthma admissions. ERJ Open Res. 2016;2:00039–2016.
   PubMedGoogle Scholar
• Majellano EC, Clark VL, Winter NA, et al. Approaches to the assessment of severe asthma: barriers and strategies. J Asthma Allergy. 2019;12:235–251.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–426.
   PubMed Web of Science ®Google Scholar
• Broersen LH, Pereira AM, Jørgensen JO, et al. Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100:2171–2180.
   PubMed Web of Science ®Google Scholar
• Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA. 2002;287(2):236–240.
   PubMed Web of Science ®Google Scholar
• Choudhury S, Lightman S, Meeran K. Improving glucocorticoid replacement profiles in adrenal insufficiency. Clin Endocrinol (Oxf). 2019;91:367–371.
   PubMed Web of Science ®Google Scholar
• Suehs CM, Menzies-Gow A, Price D, et al. Oral corticosteroids tapering delphi expert panel. expert consensus on the tapering of oral corticosteroids for the treatment of asthma. A delphi study. Am J Respir Crit Care Med. 2021;203:871–881.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bel EH, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019;5:00009–2019.
   PubMedGoogle Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2021;S2213-2600;00352–0.
   Web of Science ®Google Scholar
• Menzella F, Latorre M, Ruggiero P, et al. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy? Expert Opin Biol Ther. 2019;19(7):601–606.
   PubMed Web of Science ®Google Scholar
• Albers FC, Mullerova H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: the IDEAL study. J Asthma. 2018;55:152–160.
   PubMed Web of Science ®Google Scholar
• Kuo CS, Pavlidis S, Loza M, U-BIOPRED Study Group. T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. Eur Respir J. 2017;49:1602135.
   PubMed Web of Science ®Google Scholar
• Blakey J, Chung LP, and McDonald VM, et al. Oral corticosteroids stewardship for asthma in adults and adolescents: a position paper from the Thoracic Society of Australia and New Zealand. Respirology. 2021. doi:https://doi.org/10.1111/resp.14147. Online ahead of print.
   Google Scholar